AgonOx 
Welcome,         Profile    Billing    Logout  
 3 Products   2 Diseases  3 Products   1 Trial   49 News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MEDI6469 / AstraZeneca
NCT02274155: Anti-OX40 Antibody in Head and Neck Cancer Patients

Completed
1
17
US
Anti-OX40 antibody administration, MEDI6469, Surgical Resection
Providence Health & Services, MedImmune LLC
Head and Neck Cancer
09/17
12/23
AGX-148 / AgonOx
ACT, NCT05902520: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Recruiting
1
18
US
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
AgonOx, Inc., Phio Pharmaceuticals Corp., Providence St Joseph Health
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
05/25
05/26
AGX-405 / AgonOx
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MEDI6469 / AstraZeneca
NCT02274155: Anti-OX40 Antibody in Head and Neck Cancer Patients

Completed
1
17
US
Anti-OX40 antibody administration, MEDI6469, Surgical Resection
Providence Health & Services, MedImmune LLC
Head and Neck Cancer
09/17
12/23
AGX-148 / AgonOx
ACT, NCT05902520: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Recruiting
1
18
US
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
AgonOx, Inc., Phio Pharmaceuticals Corp., Providence St Joseph Health
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
05/25
05/26
AGX-405 / AgonOx
No trials found

Download Options